Fibrinogen-Fibronectin Matrix for Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering growth factors (GFs) for tissue regeneration, such as bone regeneration and vascularization, face challenges including rapid breakdown and clearance in vivo, leading to inadequate retention and efficacy, along with safety concerns due to high dosages required for clinical success.
Innovation Solution
A biologically active matrix comprising a physiological fibrillar fibronectin network formed on a polymer surface, which presents GFs like BMP-2 or VEGF in combination with integrin binding domains, allowing for synergistic cell signalling and reduced GF doses, using alkyl acrylate polymers like poly(ethyl acrylate) to support FN fibrillogenesis and sequester GFs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of growth factors are used to promote tissue regeneration, then bone repair and vascularization efficacy is improved, but catastrophic collateral risks and adverse effects increase
Solution Approach 1:
The patent uses a fibrinogen-fibronectin matrix as an intermediary carrier to deliver growth factors. This matrix binds and sequesters growth factors, providing controlled local delivery that maintains effective concentrations while reducing systemic exposure and associated adverse effects
Solution Approach 2:
The patent changes the delivery parameter from high-dose bolus administration to low-dose sustained release through the fibrinogen-fibronectin matrix, transforming the concentration-time profile to achieve therapeutic efficacy with reduced peak concentrations and lower total dosage
2Productivity
If growth factors are administered to enhance tissue healing, then cell growth and proliferation is stimulated, but rapid breakdown and clearance from tissue sites occurs
Solution Approach 1:
The fibrinogen-fibronectin matrix serves as an intermediary reservoir that binds growth factors through specific protein-protein interactions, protecting them from rapid clearance and providing sustained release over time
Solution Approach 2:
The patent employs preliminary action by pre-forming the fibrinogen-fibronectin matrix at the tissue site before growth factor administration, creating a protective scaffold that is already in place to bind and retain the growth factors upon delivery
3Ease of operation
If growth factors are delivered in soluble form or using simple matrix carriers, then administration is simplified, but inadequate retention and efficacy is achieved
Solution Approach 1:
The patent creates a composite material system combining fibrinogen and fibronectin proteins that work synergistically to deliver growth factors. This composite approach provides both the simplicity of a single-step delivery system and the retention benefits of protein-protein interactions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances cell growth, proliferation, and differentiation with lower GF doses, providing a safer and more effective method for tissue regeneration by colocalizing integrin and GF receptor signalling, while reducing the need for high GF concentrations and associated adverse effects.
Implementation Method 1
a material surface comprising an alkyl acrylate polymer deposited on said first surface; and a biologically active matrix assembled on said material surface, wherein said biologically active matrix comprises fibronectin (FN); and a growth factor (GF)
Data Source
AI summary
The invention provides materials presenting a biologically active matrix comprising a physiological fibrillar fibronectin network, such as implantable constructs, and their use for modulating cell behaviour and fate, including cell growth, proliferation and/or differentiation, such as for promoting tissue regeneration, for example, bone regeneration or vascularization. Also provided are constructs presenting a biologically active matrix comprising a physiological fibrillar fibronectin network for sustaining growth of stem cells or maintaining stem cells (maintaining stemness).